Improving cancer immunotherapy by targeting specific immune cells
Official title: Targeting GPR84 to Overcome Macrophage Mediated Resistance to Immunotherapy
Funded at Ohio State University · NIH-11082295 · Data updated 2026-11-12
This study is looking at how certain immune cells in tumors can make cancer treatments less effective, and it hopes to find ways to change these cells so they help fight cancer instead, which could improve treatment outcomes for people with bladder cancer and other types of tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | April 18, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $360,696 |
| NIH project number | 5R01CA269984-03 |
| Project ID | NIH-11082295 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with bladder cancer or other tumors who are undergoing or considering immunotherapy.
✕Less likely to help
Patients with tumors that do not involve macrophage-mediated resistance or those not receiving immunotherapy may not benefit from this research.
What this research studies
This research investigates how certain immune cells, specifically tumor-associated macrophages (TAMs), contribute to the resistance against cancer immunotherapy. By understanding the molecular signals that influence these macrophages, the study aims to develop strategies to reprogram them from promoting tumor growth to supporting anti-tumor immune responses. The approach focuses on the role of fatty acid signals in this transformation, which could enhance the effectiveness of existing immunotherapy treatments for cancer patients. Patients with bladder cancer and other tumors may benefit from insights gained through this research.
Why it matters
Potential benefit: If successful, this research could lead to improved outcomes for cancer patients receiving immunotherapy by overcoming resistance mechanisms.
How similar studies have gone: Other research has shown promising results in reprogramming immune cells to enhance cancer treatment, indicating that this approach has potential for success.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Xin, Gang — Ohio State University
- Study coordinator: Xin, Gang
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.